Many scientists and physicians believe in the healing power of heat, but to date, there have been no major commercial successes in hyperthermia. Hyperthermia companies suffer from the field's checkered past: a wave of commercial hyperthermia flameouts in the 1980's means that many investors won't give hyperthermia companies a second glance. First Circle Medical's challenge is to win over skeptical investors and clinicians as it pursues a new device market for hepatitis C. There it aims to offer a side effect free alternative to drugs for a deadly and prevalent disease with few therapeutic options, or, at the very least, a procedure that will potentially boost the efficacy of drugs. But as the first and only player in a new field, and in light of the prejudice against hyperthermia devices that many share, First Circle has to create a base of rigorous scientific data from scratch; indeed, it has to bear the burden of doing everything right.
by Mary Stuart
Every century has had its believers in the therapeutic power of heat. "Give me the power to create fever in...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.
Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.
